Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Conditions: Refractory or Recurrent Solid Tumors; Rhabdomyosarcoma; Non-Rhabdomyosarcoma Soft Tissue Sarcoma Interventions: Drug: Eribulin mesilate; Drug: Irinotecan hydrochloride Sponsor: Eisai Inc. Recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials